IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality Fujian Cancer Hospital, Fuzhou, Fujian Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, He Hunan Cancer Hospital, Changsha, Hunan Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Jiangsu Province Hospital, Nanjing, Jiangsu The First Affiliated Hospital of China Medical University, Shengyang, Liaoning Shandong Cancer Hospital, Jinan, Shandong Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310005, Hangzhou, Zhejiang The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Age range
18 Years and older
Last updated February 2026